It is indicated for the short-term treatment (up to 16 weeks) of erosive esophagitis associated with GERD. Other possible uses may include the maintenance treatment of erosive esophagitis, acute or maintenance treatment of duodenal or gastric ulcers, esophageal gastric varices bleeding prophylaxis, ...
Usual Starting Dose : 40mg once daily.
Maintenance Dose : 20mg once daily to be taken 30min before breakfast.
Duodenal Ulcer : 40mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed.
Gastric Ulcer : 40mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed.
Gastro-Esophageal Reflux Disease : 40mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed; may be continued at 20mg daily (long-term management), increased to 40mg daily if symptoms return.
Duodenal Ulcer Associated with Helicobacter pylori : 40mg twice daily associated with appropriate antibiotic regimen.
Ulcer induced by Nonsteroidal Anti- Inflammatory Drugs ( NSAIDs ) : 40mg daily in the morning has been used to prevent the formation of gastro-duodenal lesions in patients receiving continuous treatment with NSAIDs.
Gastrointestinal Bleeding from Stress or Acid Peptic Diseases : Adults : 40mg once daily, preferably in the morning with or without food, if required dose may be increased.
Each enteric-coated tablet contains:
Pantoprazole Sodium Sesquihydrate equivalent to Pantoprazole ... 40mg.
Pantoprazole is proton pump inhibitor. It is chemically described as Sodium 5-(difluoromethoxy)- 2- [(RS)-[ (3,4- dimethoxypyridin-2-yl)methyl] sulfinyl ]benzimid-azol-1-ide sesquihydrate. Chemical formula is C16H14F2N3NaO4S,1½ H2O and its molecular weight is 432.4.
Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion.
Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it irreversibly binds to and inhibits the H+, K+- ATPase enzyme, and inhibits the production of hydrochloric acid in the stomach. This effect leads to inhibition of both basal and stimulated gastric ac...
Absorption : Rapidly absorbed. Time to peak plasma concentration is approximately 2-2.5hrs after oral dose. Oral bioavailability is approximately 77%.
Distribution : Volume of Distribution is 11-24L. Plasma protein-binding is approximately 98%(mainly to albumin).
Metabolism : Extensive hepatic metabolism, mainly by CYP2C19 isoenzyme to desmethyl pantoprazole and slightly by CYP3A4, CYP2D6 and CYP2C9 isoenzymes.
Excretion : Mainly via urine ( approximately 80%), the remainder in faeces (via the bile ). Elimination half-life is approximately 1 hr ( prolonged in hepatic impairment; in patient with cirrhosis ; the elimination t1/2 is 3-6 hrs.
It is contraindicated in patients who have known hypersensitivity to pantoprazole or other proton pump inhibitors (PPIs).
Pantoprazole should be used with caution in patients with liver disease, in pregnancy and breastfeeding, before treatment the presence of gastric malignancy should be excluded.
Common side effects of pantoprazole include Headache, Abdominal pain, Facial puffiness, Generalized swelling (edema), Chest pain, Diarrhea, Constipation, Itching, Rash, Gas, High blood sugar (hyperglycemia), Nausea, Vomiting, Photosensitivity.
Furosemide: Combining with Pantoprazole with Furosemide can sometimes cause hypomagnesemia (low blood levels of magnesium).
Atorvastatin: Combining Pantoprazole with Atorvastatin may increase the blood levels and effects of atorvastatin.
Clopidogrel: Combining Pantoprazole with Clopidogrel may reduce the effectiveness of clopidogrel in preventing heart attack or stroke.
Levothyroxine: Taking levothyroxine with pantoprazole may interfere with the absorption of levothyroxine and reduce its effectiveness.
Store below 30℃ in cool and dry place. Protect from light and moisture. Keep out of reach and sight of children.
10 x 10’s Alu-Alu Blisters.